Evolution of multiple sclerosis treatment: next generation therapies meet next generation efficacy criteria (Q83598311)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21397566 AND SRC:MED&resulttype=core&format=json

25 January 2020

title

Evolution of multiple sclerosis treatment: next generation therapies meet next generation efficacy criteria (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21397566 AND SRC:MED&resulttype=core&format=json

25 January 2020

author name string

Hans-Peter Hartung

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21397566 AND SRC:MED&resulttype=core&format=json

25 January 2020

Orhan Aktas

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21397566 AND SRC:MED&resulttype=core&format=json

25 January 2020

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21397566

27 November 2024

publication date

1 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21397566 AND SRC:MED&resulttype=core&format=json

25 January 2020

April 2011

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21397566

full work available at URL

27 November 2024

https://api.elsevier.com/content/article/PII:S1474442211700436?httpAccept=text/xml

1 reference

10.1016/S1474-4422(11)70043-6

DOI

https://api.crossref.org/works/10.1016/S1474-4422(11)70043-6

https://api.elsevier.com/content/article/PII:S1474442211700436?httpAccept=text/plain

27 November 2024

1 reference

10.1016/S1474-4422(11)70043-6

DOI

https://api.crossref.org/works/10.1016/S1474-4422(11)70043-6

27 November 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21397566 AND SRC:MED&resulttype=core&format=json

25 January 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21397566 AND SRC:MED&resulttype=core&format=json

25 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21397566 AND SRC:MED&resulttype=core&format=json

25 January 2020

page(s)

293-295

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21397566 AND SRC:MED&resulttype=core&format=json

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

25 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(11)70043-6

7 January 2021

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(11)70043-6

7 January 2021

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(11)70043-6

7 January 2021

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(11)70043-6

7 January 2021

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(11)70043-6

7 January 2021

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(11)70043-6

7 January 2021

Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(11)70043-6

7 January 2021

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(11)70043-6

7 January 2021

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(11)70043-6

7 January 2021

Oral therapies for multiple sclerosis: are we there yet?

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(11)70043-6

7 January 2021

10.1016/S1474-4422(11)70043-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21397566 AND SRC:MED&resulttype=core&format=json

25 January 2020

1 reference